U004 When to Put Down the Scalpel: Non-surgical Therapies for Skin Cancer
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session is directed to general dermatologists. We will cover key aspects of non-surgical approaches in skin cancer treatment, including patient selection, counseling, and expected outcomes. We will cover the following non-surgical treatments and provide clinical pearls: topical medications, cryotherapy, photodynamic therapy, intralesional treatments, and systemic options. We also will cover consideration of active surveillance in select patients. We will describe patient selection for these non-surgical therapies, including consideration of co-morbidities, aversion to surgery, low-risk tumors, high tumor burden, and eruptive KAs.
LEARNING OBJECTIVES
Recognize localized skin cancer cases that would benefit most from non-surgical treatment
Select the optimal non-surgical treatment for localized skin cancer patients
Identify the risks and benefits of active surveillance for localized skin cancer
SCHEDULE
3:30 PM
Non-surgical treatments for keratinocyte carcinoma
Abigail Baird Waldman, MD, FAAD
3:45 PM
Systemic treatments for localized keratinocyte carcinoma
Emily S Ruiz, MD, FAAD
4:00 PM
Prevention and active surveillance for keratinocyte carcinoma
Rebecca I Hartman, MD, MPH, FAAD
4:15 PM
Q&A
SPEAKERS
Rebecca I Hartman, MD, MPH, FAAD
Emily S Ruiz, MD, FAAD
Abigail Baird Waldman, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Rebecca I Hartman, MD, MPH, FAAD
Almirall – Consultant (1099 relationship)(Fees); Evereden – Advisory Board(Stock), Consultant(Fees); Med Learning Group – Speaker/Faculty Education(Fees); MJH Life Sciences – Consultant (1099 relationship)(Fees); Oasis Pharmaceuticals – Data Safety Monitoring Board(Fees);
Emily S Ruiz, MD, FAAD
Castle Biosciences, Inc – Investigator(Grants/Research Funding); Checkpoint Therapeutics – Consultant (1099 relationship)(Fees); Feldan Therapeutics – Consultant (1099 relationship)(Fees); Merck – Investigator(Grants/Research Funding); Regeneron – Advisory Board(Fees), Investigator(Grants/Research Funding);
Abigail Baird Waldman, MD, FAAD
No financial relationships exist with ineligible companies.